| ¿µ¹® | liver cirrhosis | ÇÑ±Û | °£°æÈ(Áõ) |
|---|---|---|---|
| ¼³¸í | Á¤»óÀûÀÎ °£¼¼Æ÷ÀÇ ¸¹Àº ºÎºÐÀÌ ¼Ò½ÇÀÌ µÇ°í ´ë½Å¿¡ ¼¶À¯Á¶Á÷À¸·Î ´ëÄ¡µÇ¾î ÀÖ´Â °£ÀÇ º´Àû »óŸ¦ ¸»ÇÑ´Ù. °£¼¼Æ÷ÀÇ ¸¹Àº ¼Õ»óÀ» °¡Á®¿À´Â ¸ðµç º´¿¡¼ °£°æÈ°¡ ÀϾÙ. ±×·¯³ª ´ëºÎºÐÀÇ °£°æÈÀÇ ¿øÀÎÀº °£¿°°ú ¼ú¿¡ ÀÇÇÑ °£¼Õ»óÀÌ´Ù. °£°æÈÀÇ Áõ»óÀº ¿øÀο¡ µû¶ó¼ ´ÙÀ½°ú °°Àº µÎ °¡Áö·Î ³ª´ ¼ö°¡ ÀÖ´Ù. ù°´Â ¿ì¼± °£ÀÇ ±â´ÉÀÇ Àå¾Ö¿¡ ÀÇÇÑ Áõ»óÀÌ´Ù. °£¼¼Æ÷ÀÇ »ó´ç¼ö°¡ ¼¶À¯Á¶Á÷À¸·Î ´ëüµÇ¾î ÀÖ´Â »óÅÂÀ̹ǷΠ°£ÀÇ ±â´ÉÀÇ Àå¾Ö°¡ »ý±â´Â °ÍÀº ´ç¿¬ÇÏ´Ù. Ȳ´Þ µîÀÌ ´ëÇ¥Àû ¿¹¶ó ÇϰڴÙ. µÎ¹øÂ°´Â ¹®¸Æ¾ÐÇ×Áø(portal hypertension)¿¡ ÀÇÇÑ Áõ»óµéÀÌ´Ù. À§, ÀÛÀºÃ¢ÀÚ³ª ūâÀÚ¿¡¼ ¿µ¾çºÐÀ» Èí¼öÇϱâÀ§ÇÑ ¸ð¼¼Ç÷°üÁ¶Á÷Àº ¸ðµÎ °£À¸·Î ¿¬°áÀÌ µÈ´Ù. Áï ¼Òȱ⿡¼ Èí¼öÇÑ ¿µ¾çºÐÀÌ °¡µæÇÑ ÇÇ´Â ¸ðµÎ °£À¸·Î ¿¬°áµÇ´Âµ¥ À̰ÍÀ» ¹®¸Æ°è(portal system)¶ó°í ÇÑ´Ù. °£°æÈÀÇ °æ¿ì¿¡´Â ¼¶À¯¼ºÁ¶Á÷ÀÌ °£Á¶Á÷À» °ÅÀÇ ´ëÄ¡ÇÔÀ¸·Î Á¤»ó °£¼¼Æ÷³»¿¡¼± ³ÐÀº °ø°£À» Â÷ÁöÇÏ´ø °£³»ÀÇ Ç÷°üµéÀÌ ¼¶À¯Á¶Á÷¿¡ ´¸®°Ô µÈ´Ù. ±×·¯¸é À̰Ͱú ¿¬°áµÈ ¹®¸Æ°èÀÇ ¾Ð·Âµµ ³ô¾ÆÁö°Ô µÈ´Ù. ¹®¸Æ¾ÐÀÇ »ó½ÂÀÌ ÀÖ´Â °æ¿ì¿¡´Â ¹®¸Æ°è¿¡ ¿¬°áÀÌ µÇ¾î ÀÖ´Â ¸ðµç ºÎºÐÀÇ Á¤¸ÆÀÇ ¾Ð·ÂÀÌ ³ô¾ÆÁö°í Á¤¸ÆÀÇ ¼øÈ¯ÀÌ Á¤ÁöµÈ »óŰ¡ µÈ´Ù. Áö¶óÀÇ °æ¿ìµµ ¹®¸Æ°è¿¡ ¿¬°áµÈ Àå±âÀ̹ǷΠ¹®¸Æ¾Ð »ó½Â½Ã¿¡´Â Á¤¸ÆÀÇ ¼øÈ¯ÀÌ ¾ø¾îÁö°í, µ¿¸ÆÀ¸·Î À¯ÀÔÀÌ µÇ´Â Ç÷¾×Àº °è¼Ó µé¾î¿À¹Ç·Î Áö¶óÀÌ Ä¿Áö°Ô µÈ´Ù. ¶Ç ¼ÒȱâÀÇ ¸ð¼¼Ç÷°ü³»¿¡¼ÀÇ ¾Ð·Âµµ ³ô¾ÆÁö°Ô µÇ°í ±×·¯¸é ±× ¾Ð·Â¿¡ ÀÇÇØ¼ ¸¹Àº ¾çÀÇ ¼öºÐÀÌ ¸ð¼¼Ç÷°ü¹ÛÀ¸·Î ºüÁ®³ª¿À°Ô µÈ´Ù. ÀÌ ¼öºÐÀÌ ¸ð¿© º¹¼ö°¡ µÈ´Ù. |
||
| ¿µ¹® | liver function tests | ÇÑ±Û | °£±â´É°Ë»ç |
|---|---|---|---|
| ¼³¸í | Ç÷¾×°Ë»çÁß °¡Àå ¸¹ÀÌ ¾²ÀÌ´Â °Ë»ç¹ýÀ¸·Î ´ÙÀ½ 7°¡Áö¸¦ °Ë»çÇÏ°Ô µÈ´Ù. Ç÷ûÄÝ·¹½ºÅ×·Ñ, ÃѴܹéÁú, ¾ËºÎ¹Î, ºô¸®·çºó, GOT/GPT È¿¼Ò, ¾ËÄ®¸®ÀλêºÐÇØÈ¿¼Ò(alkaline phophatase) µîÀ» °Ë»çÇÏ°Ô µÇ´Â µ¥ °¢ °Ë»çÄ¡¿¡´Â ¸ðµÎ Àǹ̰¡ ÀÖÀ¸¸ç, ÀÌ °Ë»ç Çϳª·Î °£±â´ÉÀÇ Àü¹ÝÀûÀÎ »óÅ¿¡ ´ëÇØ¼ ¾Ë¾Æº¼ ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | liver biopsy | ÇÑ±Û | °£»ý°Ë |
|---|---|---|---|
| ¼³¸í | »ç¶÷ÀÌ »ì¾ÆÀÖ´Â »óÅ¿¡¼ º´Å͸¦ Àß¶ó³»¾î Á÷Á¢ Çö¹Ì°æ µîÀ¸·Î º¸¾Æ Áø´ÜÀ» ³»¸®´Â Áø´Ü¹ýÀÌ´Ù. °£»ý°ËÀº ÁÖ·Î °£¿°À̳ª °£¾ÏÀÇ Áø´ÜÀ̳ª, Èñ±ÍÇÑ À¯Àüº´, ¼±Ãµº´ µîÀÇ È®Áø¿¡ ÀÌ¿ëµÈ´Ù. °£¿°¿¡¼´Â ÇöÀçÀÇ °£¿°ÀÌ ÁøÇ༺ÀÎÁö ȤÀº ºñÁøÇ༺ÀÎÁö ¶Ç´Â ÀÌ¹Ì °£°æÈ»óÅ·Π³Ñ¾î°¬´ÂÁö µîÀÇ ¿©ºÎ¸¦ ¾Ë¾Æº¸°Ô µÈ´Ù. |
||
| ¿µ¹® | hepatitis | ÇÑ±Û | °£¿° |
|---|---|---|---|
| ¼³¸í | °£¿¡ »ý±â´Â ¿°ÁõÀ» ÅëÆ²¾î À̸£´Â ¸». ¹ß¿-Ȳ´Þ-Àü½Å±ÇÅÂ-¼ÒÈ Àå¾ÖÀÇ Áõ»óÀ» º¸À̴µ¥, ÁÖµÈ ¿øÀÎÀº À½½Ä¹°°ú Ç÷¾×À» ÅëÇÑ ¹ÙÀÌ·¯½º °¨¿°ÀÌ¸ç ±× ¹Û¿¡ ¾à¹°, ¾ËÄÚ¿Ã, ¾Ë·¹¸£±â µîÀÌ ¿øÀÎÀÎ °Íµµ ÀÖ´Ù. ÀÌ °£¿°Àº ±× Áö¼Ó±â°£¿¡ µû¶ó¼ ±Þ¼º°£¿°°ú ¸¸¼º°£¿°À¸·Î ³ª´©´Âµ¥, ¸¸¼º°£¿°Àº 6°³¿ù ÀÌ»ó °£¿°ÀÌ Áö¼ÓµÇ´Â °æ¿ì¸¦ ¸»ÇÏ°í ±Þ¼º°£¿°Àº 6°³¿ù ÀÌ»ó Áö¼ÓÇÏÁö ¸øÇÏ´Â °æ¿ì¸¦ ¸»ÇÑ´Ù. ±Þ¼º°£¿°Àº ¸·¿¬ÇÑ ¸íĪÀ¸·Î¼, °£ÀÇ ±Þ¼º-½ÇÁú¼º »óÇØÀÇ °ÅÀÇ ÀüºÎ¸¦ Æ÷°ýÇÏ´Â ³ÐÀº °³³äÀÌÁö¸¸, ½ÇÁ¦´Â ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î »ý±â´Â °£¿°ÀÌ ´ëºÎºÐÀÌ´Ù. ¹ÙÀÌ·¯½º¼º °£¿°Àº À¯Ç༱°£¿°(AÇü)°ú Ç÷û°£¿°(BÇü)ÀÇ µÎ Á¾·ù°¡ Àִµ¥, À̵éÀº ¸ðµÎ Àü¿°¼º ÁúȯÀÌÁö¸¸ °¨¿° °æ·Î´Â ´Ù¸£´Ù. °¨¿° °æ·Î·Î À¯Ç༱°£¿°¹ÙÀÌ·¯½º´Â Ç÷¾×-»ùâÀÚ¾×-´ëº¯ Áß¿¡¼ Áõ¸íµÇ¹Ç·Î Àü¿°µÈ ¹°-À½½ÄÀ» ÅëÇÏ¿© °æ±¸°¨¿°µÇ°Å³ª ȯÀÚ¿ÍÀÇ Á÷Á¢ Á¢ÃË¿¡ ÀÇÇØ¼ °¨¿°µÈ´Ù. Ç÷û°£¿°Àº ¿À·ÎÁö ºñ°æ±¸Àû °¨¿°À¸·Î ȯÀÚÀÇ Ç÷û, Ç÷¾×ÀÇ ÁÖ»ç, ȯÀÚÀÇ Ç÷¾×¿¡ °¨¿°µÈ ÁÖ»ç±â µîÀ¸·Î °¨¿°µÈ´Ù. Àẹ±â´Â À¯Ç༺°£¿°ÀÌ 2~6ÁÖ°£À̰í, Ç÷û °£¿°Àº 6ÁÖ~6°³¿ù °¡·® µÈ´Ù. Ç÷û°£¿°Àº À¯ÇàÀÇ °èÀý-¿¬·É°ú´Â °ü°è°¡ ¾øÀ¸³ª, À¯Ç༺°£¿°Àº ÁÖ·Î °¡À»¿¡¼ °Ü¿ï¿¡ °ÉÃÄ ¸¹°í û¼Ò³â¿¡ ¸¹´Ù. Áõ¼¼´Â ¹ßº´Çϱâ 1ÁÖÀÏ ÀüºÎÅÍ ¿Â¸öÀÌ ³ë°ïÇÏ°í ½Ä¿åÀÌ ¶³¾îÁö¸ç µÎÅëÀÌ ÀÖ°í »óº¹ºÎ¿¡ ºÒÄè°¨ÀÌ »ý±â´Âµ¥, À¯Ç༺°£¿°¿¡¼´Â Ȳ´ÞÀÌ ³ªÅ¸³ª±â Àü¿¡ ¹ß¿(38¡É ÀüÈÄ)ÀÌ ÀÖÀ» ¶§°¡ ¸¹°í ¼öÀÏ ÈÄ¿¡ ÇØ¿µÈ´Ù. ¶Ç, °üÀý-Ç㸮°¡ ¾ÆÇà ¶§µµ ÀÖ¾î óÀ½¿¡´Â °¨±â·Î ¿ÀÀÎÇÒ ¶§°¡ ¸¹´Ù. Ç÷û°£¿°Àº ÀÌ·¯ÇÑ Ãʱâ Áõ¼¼°¡ °¡º±°í ¼¼È÷ ¹ßº´ÇÏ´Â °ÍÀÌ ¸¹´Ù. ÁÖÁõ¼¼´Â À§ÀåÁõ¼¼¿Í Ȳ´ÞÀ̸ç, ½Ä¿åºÎÁø-±¸Åä-±¸¿ªÁú, »óº¹ºÎÀÇ µÐÅë µîÀÌ ÀϾ¸ç, ¹ßº´ ÈÄ 4~5ÀÏ¿¡ Ȳ´ÞÀÌ ³ªÅ¸³´Ù. Ȳ´ÞÀº 1ÁÖÀÏÀ» ÀüÈÄÇÏ¿© ÃÖ°í¿¡ À̸£¸ç, ±× ÈÄ 1°³¿ù »çÀÌ¿¡ ¾ø¾îÁö¸é¼ ´Ù¸¥ Áõ¼¼µµ ÁÁ¾ÆÁø´Ù. °æ°ú´Â ±Þ¼º°£¿°Àº ¾à 70%°¡ ´ë°³ 1~3°³¿ù À̳»¿¡ Ä¡À¯µÇÁö¸¸ »¡¸® Ä¡·áµÇÁö ¾Ê´Â °Í Áß 15%°¡ ¸¸¼º°£¿°À¸·Î ÀÌÇàÇϸç, ±× ÀϺδ °£°æÈÁõÀ¸·Î ÀÌÇàÇÑ´Ù. ±Þ¼º°£¿° Áß¿¡´Â ¶§·Î´Â 10ÀÏ À̳»¿¡ »ç¸ÁÇÏ´Â Àü°Ý¼º°£¿°À̶ó°í ÇÏ´Â °Íµµ ÀÖ´Ù. º´ÀÇ Àüü °æ°ú Áß È²´ÞÀÌ ³ªÅ¸³ªÁö ¾Ê´Â ¹«È²´Þ¼º °£¿°À̶ó°í ÇÏ´Â °Íµµ ÀÖ¾î. ¸¸¼º°£¿°À¸·Î ÀÌÇàÇÏ´Â °Í¿¡´Â ÀÌ ¹«È²´Þ¼ºÀÌ ¸¹Àº °æÇâÀÌ ÀÖ´Ù. Ç÷û°£¿°µµ ¸¸¼ºÈÇϱ⠽±´Ù. |
||
| AFP | Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265] ; Oncofetal Antigens &nbs... |
|---|---|
| FLC | family life cycle; fatty liver cell; fetal liver cell; Friend leukemia cell |
| AH | abdominal hysterectomy; absorptive hypercalciuria; accidental hypothermia; acetohexamide; acid hydro... |
| FAP | familial adenomatous polyposis; familial amyloid polyneuropathy; fatty acid polyunsaturated; fatty a... |
| AFLP | acute fatty liver of pregnancy |
| AFLP | Acute fatty liver of pregnancy |
|---|---|
| FLHS | Fatty Liver Haemorrhagic Syndrome |
| FLKS | Fatty Liver and Kidney Syndrome |
| L-FABP | Liver fatty acid binding protein |
| FA | 2-fatty acid |
| fatty liver | <radiology> Hyperalimentation, diabetes, Cushing disease, steroids, obesity, previous jejunal bypass, Reye syndrome, kwashiorkor, malnutrition (EtOH, chemo, RT), Crohn disease (12 Dec 1998) |
|---|---|
| fatty liver, alcoholic | Fatty liver in alcoholics. It is potentially reversible and may be associated with alcoholic hepatitis or cirrhosis. (12 Dec 1998) |
| fatty liver syndrome | <syndrome> A noninfectious disease of chickens characterised by enlarged fat-infiltrated livers. (05 Mar 2000) |
| activated fatty acid | A fatty acyl-coenzyme A thiol ester. (05 Mar 2000) |
| branched-chain fatty-acid-kinase | <enzyme> From anaerobic spirochete ma-2 Registry number: EC 2.7.2.14 Synonym: isovalerate kinase, 2-methylbutyrate kinase, isobutyrate kinase (26 Jun 1999) |
| branched-chain fatty acid synthetase | <enzyme> Analogous to fatty acid synthetase complex but starting with a branched chain keto acid; from bacillis subtilis Registry number: EC 2.3.1.- Synonym: bcfa synthetase (26 Jun 1999) |
| volatile fatty acid number | An index of the volatile acid content of a fat; the number of milliliters of 0.1 n KOH required to neutralise the soluble volatile fatty acids in 5 g of fat that has been saponified, acidified to liberate the fatty acids, and then steam-distilled. Synonym: volatile fatty acid number. (05 Mar 2000) |
| monounsaturated fatty acids | A fatty acid chain with at least two empty spaces that could be hydrogenated (have a hydrogen atom added). Saturated (hydrogenated) fatty acids are a greater health risk for the development of atherosclerotic vascular disease. (27 Sep 1997) |
| polyenoic fatty acid isomerase | <enzyme> Catalyses conversion of arachidonic acid and 5,8,11,14,17-eicosapentaenoic acid to 5,7,9,14-eicosatetraenoic acid and 5,7,9,14,17-eicosapentaenoic acid, respectively Registry number: EC 5.3.3.- Synonym: pfi enzyme (26 Jun 1999) |
| saturated fatty acid | A fatty acid, the carbon chain of which contains no ethylenic or other unsaturated linkages between carbon atoms (e.g., stearic acid and palmitic acid); called saturated because it is incapable of absorbing any more hydrogen. (05 Mar 2000) |
| saturated fatty acids | In eukaryotic membranes refers to stearic, palmitic and myristic acids, that are linear aliphatic chains with no double bonds. Prokaryotes have numerous branched chain saturated fatty acids. (18 Nov 1997) |
| xenobiotic medium chain fatty acid - coenzyme A ligase | <enzyme> Partial amino acid sequence of enzyme from bovine liver mitochondria given I first source; has high sequence homology to human and rat sa protein Registry number: EC 6.2.1.- Synonym: xl-i ligase, xl-i carboxylic acid - CoA ligase (26 Jun 1999) |
| delta-13 fatty acid desaturase | <enzyme> Involved in sex pheromone biosynthesis from palmitic acid in the moth thaumetopoea pityocampa, acts in conjunction with an 11-desaturase Registry number: EC 1.14.99.- Synonym: delta-13 desaturase (26 Jun 1999) |
| delta-22 fatty acid desaturase | <enzyme> Involved in ergosterol biosynthesis Registry number: EC 1.14.99.- Synonym: ergosta-5,7-dien-3 beta-ol delta-22 desaturase (26 Jun 1999) |
| diethenoid fatty acid | A fatty acid containing two double bonds, e.g., linoleic acid. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|